G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
about
Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin LymphomaAdapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.Minimizing late effects in children and adults with Hodgkin lymphoma - the beginning of the end for radiation therapy.The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496Chemotherapy only for localized Hodgkin lymphoma.Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia.Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma.Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.Managing advanced stage Hodgkin lymphoma.Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support.The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD.Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.Hodgkin's lymphoma--long-term outcome: an experience from a tertiary care cancer center in North India.
P2860
Q34104990-3DFC48DF-85E0-40AF-A13C-0C584FA93192Q35038832-227AC3AF-365E-4DD7-9779-D8EC43773ACDQ37126978-9CA81096-EF99-462C-B0EF-C7F4EAF0D0EDQ37138259-129FB91F-0D88-4870-857A-F07643299B98Q37157419-64E77B77-4461-42B0-AD21-C3D5AFA74C41Q37532169-D8A706A2-4445-4FB8-B013-FD45E18C2B3BQ37888802-D0E9B797-5D00-44FE-997A-06A5642905B6Q38109529-747C67A3-31D2-46AB-9BFA-930A55B81BBEQ38786377-9F0E075B-A87B-48D8-BDE0-AEAE12C039D3Q38978471-8B55600B-2D0E-4BF4-9F6E-2AE4EC8CA7CCQ40319011-6C706BC9-A501-495E-9A3C-CC8E1C87784DQ42423722-4AE1FBAD-45D0-4E27-9111-BC1C13913DB4Q44462626-4D7D80CC-8DF2-4193-ABFA-B1C129D44F2FQ46379382-DDC8D6D0-DEC2-4E15-9B6D-F997E90852F4Q46394295-BD577E83-CE0D-4610-9819-7BB457A070AAQ49276879-0EABF991-0C9B-4C4B-943D-FF6574177D5EQ50892830-98E2C1F3-E280-469A-B59B-3B74EEC1B4CDQ51456724-84F257F0-C905-4588-8364-262EAF42B6CA
P2860
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
G-CSF is not necessary to main ...... utcomes in a 10-year analysis.
@en
G-CSF is not necessary to main ...... utcomes in a 10-year analysis.
@nl
type
label
G-CSF is not necessary to main ...... utcomes in a 10-year analysis.
@en
G-CSF is not necessary to main ...... utcomes in a 10-year analysis.
@nl
prefLabel
G-CSF is not necessary to main ...... utcomes in a 10-year analysis.
@en
G-CSF is not necessary to main ...... utcomes in a 10-year analysis.
@nl
P2093
P2860
P50
P1476
G-CSF is not necessary to main ...... utcomes in a 10-year analysis.
@en
P2093
Alfred Rademaker
Charles L Bennett
Connie Augustyniak
Daina Variakojis
Jane N Winter
Jeffrey Cilley
Kara Catsaros
Mrinal Gounder
Nanjiang Hou
Sarah Miyata
P2860
P304
P356
10.1111/J.1365-2141.2007.06598.X
P407
P577
2007-04-24T00:00:00Z